232 related articles for article (PubMed ID: 29543042)
1. Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease.
Redente EF; Aguilar MA; Black BP; Edelman BL; Bahadur AN; Humphries SM; Lynch DA; Wollin L; Riches DWH
Am J Physiol Lung Cell Mol Physiol; 2018 Jun; 314(6):L998-L1009. PubMed ID: 29543042
[TBL] [Abstract][Full Text] [Related]
2. Stattic alleviates pulmonary fibrosis in a mouse model of rheumatoid arthritis-relevant interstitial lung disease.
Xie L; Li Y; Tang W; Zhang Q; Luo C; Long X
Exp Biol Med (Maywood); 2023 Apr; 248(8):712-721. PubMed ID: 36941782
[TBL] [Abstract][Full Text] [Related]
3. A novel model of rheumatoid arthritis-associated interstitial lung disease in SKG mice.
Keith RC; Powers JL; Redente EF; Sergew A; Martin RJ; Gizinski A; Holers VM; Sakaguchi S; Riches DW
Exp Lung Res; 2012 Mar; 38(2):55-66. PubMed ID: 22185348
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment with Janus kinase inhibitor and nintedanib for rheumatoid arthritis with progressive interstitial lung disease: A case report.
Mochizuki T; Yano K; Ikari K; Okazaki K
Mod Rheumatol Case Rep; 2023 Jun; 7(2):350-353. PubMed ID: 37061836
[TBL] [Abstract][Full Text] [Related]
6. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
Makino S
Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
[TBL] [Abstract][Full Text] [Related]
7. Effects of nintedanib on the microvascular architecture in a lung fibrosis model.
Ackermann M; Kim YO; Wagner WL; Schuppan D; Valenzuela CD; Mentzer SJ; Kreuz S; Stiller D; Wollin L; Konerding MA
Angiogenesis; 2017 Aug; 20(3):359-372. PubMed ID: 28283856
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
9. Potential Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment and Computational Approach for Future Drug Development.
Jeong E; Hong H; Lee YA; Kim KS
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473928
[TBL] [Abstract][Full Text] [Related]
10. Suppression of epithelial abnormalities by nintedanib in induced-rheumatoid arthritis-associated interstitial lung disease mouse model.
Miura Y; Ohkubo H; Niimi A; Kanazawa S
ERJ Open Res; 2021 Oct; 7(4):. PubMed ID: 34881329
[TBL] [Abstract][Full Text] [Related]
11. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
[TBL] [Abstract][Full Text] [Related]
12. Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial.
Matteson EL; Aringer M; Burmester GR; Mueller H; Moros L; Kolb M
Clin Rheumatol; 2023 Sep; 42(9):2311-2319. PubMed ID: 37209188
[TBL] [Abstract][Full Text] [Related]
13. Simiao pill attenuates collagen-induced arthritis and bleomycin-induced pulmonary fibrosis in mice by suppressing the JAK2/STAT3 and TGF-β/Smad2/3 signalling pathway.
Ba X; Wang H; Huang Y; Yan J; Han L; Lin W; Shen P; Huang Y; Yang S; Qin K; Tu S; Chen Z
J Ethnopharmacol; 2023 Jun; 309():116274. PubMed ID: 36841380
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib Ameliorates Bleomycin-Induced Pulmonary Fibrosis, Inflammation, Apoptosis, and Oxidative Stress by Modulating PI3K/Akt/mTOR Pathway in Mice.
Pan L; Cheng Y; Yang W; Wu X; Zhu H; Hu M; Zhang Y; Zhang M
Inflammation; 2023 Aug; 46(4):1531-1542. PubMed ID: 37160579
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in rheumatoid arthritis-associated interstitial lung disease.
Juge PA; Crestani B; Dieudé P
Curr Opin Pulm Med; 2020 Sep; 26(5):477-486. PubMed ID: 32701675
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib induces gene expression changes in the lung of induced-rheumatoid arthritis-associated interstitial lung disease mice.
Mikami S; Miura Y; Kondo S; Sakai K; Nishimura H; Kyoyama H; Moriyama G; Koyama N; Noguchi H; Ohkubo H; Kanazawa S; Uematsu K
PLoS One; 2022; 17(6):e0270056. PubMed ID: 35714115
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
[TBL] [Abstract][Full Text] [Related]
18. Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Ghazipura M; Mammen MJ; Herman DD; Hon SM; Bissell BD; Macrea M; Kheir F; Khor YH; Knight SL; Raghu G; Wilson KC; Hossain T
Ann Am Thorac Soc; 2022 Jun; 19(6):1040-1049. PubMed ID: 35499854
[No Abstract] [Full Text] [Related]
19. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
20. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
